More than 200 mutations in the skeletal muscle a-actin gene (ACTA1) cause either dominant or recessive skeletal muscle disease. Currently, there are no specific therapies. Cardiac a-actin is 99% identical to skeletal muscle a-actin and the predominant actin isoform in fetal muscle. We previously showed cardiac a-actin can substitute for skeletal muscle a-actin, preventing the early postnatal death of Acta1 knock-out mice, which model recessive ACTA1 disease. Dominant ACTA1 disease is caused by the presence of 'poison' mutant actin protein.
INTRODUCTION
Skeletal muscle a-actin is one of six actin proteins in higher eukaryotes and is the predominant isoform expressed in postnatal skeletal muscle, where it is fundamental to muscle contraction. Mutations in the ACTA1 gene encoding the human isoform of this protein can cause devastating diseases (1) . All patients with ACTA1 disease have weakness and hypotonia leading to a reduced ability to move, breathe and swallow (2) , apart from one exceptional patient described to have hypertonia (3) . Around 50% of ACTA1 disease patients die within the first year of life (2) . However, ACTA1 disease shows a spectrum of clinical phenotypes, with some patients having mild disease compatible with adulthood survival (4) and/or adult onset (5) .
The pathological features identified in patients' skeletal muscle biopsies may include excess actin filaments, nemaline bodies, intranuclear rods (6), fibre-type disproportion (7), cores (8) , caps (9) , zebra bodies (10) and dystrophic features (11, 12) , but also minimal change myopathy (8) . Some biopsies have only one predominant pathology, but others show a combination of features (13, 14) . These findings support the hypothesis that the structural lesions comprise a pathological continuum rather than distinct, separate entities (1) .
The majority of ACTA1 disease patients have only a single, mostly de novo, dominant mutation (2) . Despite the presence of normal skeletal muscle a-actin protein, the expression of the mutant isoform gives rise to disease, presumably through a 'poison protein' or 'dominant gain of function' mechanism * To whom correspondence should be addressed at: Western Australian Institute for Medical Research, Ground Floor, B Block, QEII Medical Centre, Nedlands, WA 6009, Australia. Tel: +61 893461981; Email: kristen.nowak@uwa.edu.au (15) . About 10% of patients have recessive ACTA1 disease as a result of genetic or functional null mutations (2) , with some recessive ACTA1 disease patients when tested having a complete absence of skeletal muscle a-actin protein (10) .
Only symptomatic treatment, e.g. respiratory support is currently available for ACTA1 disease patients, and although this brings significant benefit (16) , there is a need to investigate therapeutic approaches that address the fundamental disease mechanism/s.
A number of potential treatments have been indicated or investigated. For example, anecdotal evidence suggests endurance exercise training may be beneficial for at least some less severely affected patients with certain ACTA1 mutations (1, 17) . Nguyen et al. (18) experimentally investigated using genetic methodologies three factors that induce myofibre hypertrophy, and also tested oral L-tyrosine administration in a dominant ACTA1 disease mouse model (knock-in Acta1
H40Y
). They transgenically introduced three factors that cause muscle hypertrophy: four and a half LIM domains 1 (FHL1), insulin-like growth factor 1 (IGF1) and c-ski to the Acta1 H40Y mouse model. All three factors induced muscle hypertrophy. FHL1 and IGF1, but not c-ski also increased muscle strength and returned mobility to normal levels, but none increased survival. Nguyen et al. (18) tested oral delivery of L-tyrosine, since oral L-tyrosine had been reported to be of benefit in a small number of nemaline myopathy patients (19, 20) . Four weeks of oral L-tyrosine increased muscle weight, forearm strength mobility, but an effect on survival was not tested (18) .
Another method of therapy for genetic disorders, which has been used in clinical practice, is the upregulation of one member of a protein family to compensate for the lack of another member from that family. This has been investigated for muscle diseases, most notably for utrophin in dystrophindeficiency (21) (22) (23) . However, the most widely known and used example of such upregulation is upregulation of fetal hemoglobin to treat diseases associated with the adult hemoglobins such as thalassemia and sickle-cell anemia (24) .
We previously evaluated the extent to which cardiac a-actin could functionally replace skeletal muscle a-actin in skeletal muscle. Skeletal muscle a-actin protein in mammals shares 99% identity with cardiac a-actin, differing at only four out of 375 amino acid positions. Cardiac a-actin (expressed from the ACTC gene in humans) is the predominant isoform of actin in the adult heart (25) . Additionally, during fetal development, cardiac a-actin is expressed at high levels in skeletal muscle, but expression declines close to birth (17) so that only negligible levels (,5%) are found in postnatal skeletal muscles (25) . Exceptions to this are recessive ACTA1 disease patients who retain expression of cardiac a-actin in their skeletal muscles after birth (5, 10) , with higher levels detected in better functioning patients (10) . We bred transgenic mice over-expressing cardiac a-actin in postnatal skeletal muscles (TgACTC) with skeletal muscle a-actin knock-out mice (KOActa1 2/2 ) (26). The latter mice die by postnatal day 9 (27) . In our study, .93% of KOActa1 2/2 .TgACTC mice survived to at least 3 months, and many beyond 2 years, with no functional behavioral deficits (26) . These proof of principle experiments indicated that the striated muscle a-actins are functionally interchangeable in postnatal skeletal muscle and that cardiac a-actin upregulation is a candidate treatment for recessive ACTA1 disease.
For dominant ACTA1 disease, multiple observations support the notion that changing the ratio of mutant skeletal muscle a-actin to total striated muscle a-actin (the sum of cardiac and skeletal muscle a-actins) may affect the severity of the disease. These include:
(1) Mildly or seemingly unaffected somatic mosaic parents of severely affected children with dominant ACTA1 disease suggest a reduced proportion of mutant a-actin protein is associated with survival into adulthood and very mild clinical symptoms for multiple ACTA1 mutations (6, 15) . (2) Around 15% of a-actin in the heart of dominant ACTA1 disease patients should be mutant skeletal muscle a-actin (17, 28) , yet cardiac involvement in dominant ACTA1 disease patients is only rarely reported (29) . (3) Extraocular muscles express similarly high levels of cardiac a-actin to the mature heart (28), and even severely affected ACTA1 disease patients do not have ophthalmoplegia (30) . (4) The severity of disease in mouse models of dominant ACTA1 disease appears to correlate with the ratio of mutant to wildtype skeletal muscle a-actin protein (31).
We therefore tested experimentally whether over-expression of cardiac a-actin might ameliorate the phenotype of dominant skeletal muscle a-actin disease. We crossed the same TgACTC mouse line with two dominant skeletal muscle a-actin disease mouse models; TgACTA1 
RESULTS

ACTA1
D286G .Acta1 1/2 .ACTC mice: bodyweight and survival
D286G .Acta1 +/2 pups were indistinguishable from littermate controls at birth and during the very early neonatal period, but by postnatal day 10 were significantly smaller than their littermates (31) . Approximately, 59% presented with splayed legs by postnatal day 18 and showed reduced mobility, requiring euthanasia. Introduction of the ACTC transgene resulted in a dramatic and significant extension in survival for ACTA1 D286G .Acta1 +/2 mice (Fig. 1A) , with only 9% of ACTA1 D286G .Acta1 +/2 .ACTC mice dying by postnatal day 18 and 88% surviving to at least 60 days of age. All ACTA1 D286G .Acta1 +/+ .ACTC mice (littermate controls for ACTA1 D286G .Acta1 +/2 .ACTC mice) had a normal lifespan (data not shown), similar to TgACTA1 D286G+/+ mice (31). As per previous findings (31) , the body mass of ACTA1 D286G .Acta1 +/2 mice at postnatal day 12 was significantly reduced from wild-type mice (Fig. 1B) . Although the weights of ACTA1 D286G .Acta1 +/2 .ACTC mice also varied significantly from wild-type mice, they were significantly heavier than ACTA1 D286G .Acta1 +/2 mice (Fig. 1B) . .Acta1 +/+ .ACTC mice, indicating the ACTC transgene partially restored myofibre diameter ( Fig. 2A) .
Variation in myofibre sizes and structural lesions similar to those seen in ACTA1 D286G .Acta1 +/2 muscles were apparent in ACTA1 D286G .Acta1 +/2 .ACTC gastrocnemius muscle at day 12 ( Fig. 2B ). Gastrocnemius muscles of adult (3 -4 months old) ACTA1 D286G .Acta1 +/2 .ACTC mice had evident nemaline bodies (Fig. 2C) , internally located nuclei, large variation in myofibre sizes and ringbinden ( Fig. 2C and D) .
D286G .Acta1 1/2 .ACTC mice: cardiac a-actin and mutant D286G skeletal muscle a-actin levels Cardiac a-actin immunohistochemistry was performed to confirm the expression of the ACTC transgene in adult ACTA1 D286G .Acta1 +/2 .ACTC mice. Cardiac a-actin was preferentially expressed in MHCIIB myofibres in ACTA1 D286G .Acta1 +/2 .ACTC mice, while cardiac a-actin expression in age-matched wild-type mice was minimal, except for within intrafusal myofibres (arrow; Fig. 3A ). Increased relative levels of cardiac a-actin in the skeletal muscles of both ACTA1 D286G .Acta1 +/2 .ACTC and ACTA1 D286G .Acta1
ACTC mice when compared with wild-type mice were corroborated by western blotting ( Fig. 3B and C). The contribution of mutant D286G skeletal muscle a-actin to the total striated a-actin protein pool was determined by mass spectrometry (Fig. 3D) . In ACTA1 D286G .Acta1 +/2 pups, 40% of the total striated a-actin pool was the mutant D286G protein, whereas in ACTA1 D286G .Acta1 +/2 .ACTC mice it was 20%, similar to mildly affected TgACTA1 D286G+/+ mice ( Fig. 3D ) and (31) . Thus the presence of the ACTC transgene was associated with reduced levels of mutant D286G protein. (Fig. 3D) , for the total distance run per day (Fig. 4A) , the average speed (Fig. 4B) and maximum speed (Fig. 4C) .
Acta1
H40Y .ACTC mice: bodyweight, survival and breeding
On an R1-129 genetic background, 52-61% of male Acta1 H40Y+/2 mice die by 13 weeks of age, whereas only 3 -5% of female Acta1 H40Y+/2 mice die by this time (18) . Additionally both male and female KIActa1 H40Y+/2 mice had significantly decreased bodyweights compared with their littermate controls (18) . Thus the male mice model moderately severe human dominant disease (2) . We compared survival of male Acta1 H40Y .ACTC and Acta1 H40Y mice on the CBB6F1 background (Fig. 5A ). Both groups had only 20% survival by 6 months of age (Fig. 5A) , with no increase in survival associated with the presence of the ACTC transgene. There was no increased mortality of female Acta1 H40Y+/2 and Acta1 H40Y .ACTC mice compared with wildtype mice (data not shown).
Both male and female Acta1
H40Y
.ACTC and Acta1 H40Y male mice weighed significantly less than sex-matched wild-type mice on the CBB6F1 genetic background (Fig. 5B) .
We were unable to produce homozygous Acta1 H40Y+/+ mice and in fact never derived offspring from KIActa1 H40Y+/2 male mice, even when they were mated with wild-type females, suggesting these mice were infertile. .Acta1 +/2 .ACTC muscle (n ¼ 10) compared with WT (n ¼ 2; P , 0.05); ACTA1 D286G (n ¼ 2; P , 0.05) and ACTA1 D286G.
Acta1 +/2 (n ¼ 6; P , 0.01) mice (all aged between postnatal day 10-17; one-way ANOVA). The difference in cardiac a-actin abundance between ACTA1 D286G .Acta1 +/2 .ACTC (n ¼ 10) and ACTA1
D286G
.Acta1 +/+ .ACTC (n ¼ 3) muscle was not significant. * P , 0.05, * * P , 0.01. (D) Contribution of mutant D286G skeletal muscle a-actin to the total striated muscle a-actin protein pool, as determined by mass spectrometry on gastrocnemius muscle lysates (all aged between postnatal day 10-17), was significantly lower in ACTA1
.Acta1 +/2 .ACTC (n ¼ 10) muscle compared with ACTA1 D286G .Acta1
+/2 muscle (n ¼ 5) (one-way ANOVA, P , 0.0001). D286G abundance was significantly greater in ACTA1
.Acta1 +/2 mice compared with WT (P , 0.0001) and ACTA1 D286G (n ¼ 5) mice (P , 0.001); and in ACTA1
.Acta1 +/2 .ACTC (P , 0.001) and ACTA1 D286G (P , 0.01) mice compared with WT mice, but was not significantly different between ACTA1 D286G .Acta1 +/2 .ACTC and ACTA1 D286G mice (P . 0.05). Legend same as for Figure 3C . H40Y .ACTC mice (of both sexes) showed nemaline bodies and large regions of thin filament aggregates, but these were not visible in soleus muscles (Fig. 6A) . Gomori trichrome and hematoxylin and eosin staining of tibialis anterior muscle showed paler regions correlating with thin filament accumulations (Fig. 6B) . The presence of nemaline bodies and thin filament accumulations (actin lakes) was confirmed in EDL and gastrocnemius muscles by electron microscopy (Fig. 6C) . At 6 months of age, gastrocnemius muscles from Acta1 H40Y .ACTC (of both sexes) mice also demonstrated striking pathological features, including nemaline bodies (Fig. 6D) .
Acta1
H40Y .ACTC mice: cardiac a-actin levels By immunohistochemistry, endogenous cardiac a-actin expression was increased in skeletal muscles from 4-week-old Acta1 H40Y mice (both sexes) compared with wild-type littermates ( Fig. 7A and B, respectively) . Cardiac a-actin was detected in myofibres that were negative for developmental MHC, indicating expression in non-regenerating myofibres (Fig. 7A) . Immunostaining demonstrated that endogenous cardiac a-actin was detected in MHC IIB myofibres of Acta1
H40Y
gastrocnemius muscle (Fig. 7C ). Western blotting (Fig. 7D ) also showed high levels of cardiac a-actin in Acta1
.ACTC muscle compared with wild-type, but of similar levels to that in Acta1 H40Y muscle (Fig. 7E ).
Acta1
H40Y .ACTC mice: voluntary running wheel activity
Analysis of voluntary running wheel activity of both male and female 1-month-old Acta1 H40Y mice demonstrated a significant decrease in distance covered, average speed and maximum speed compared with wild-type mice (Fig. 8A, B and C) . The decreased performance was not improved by the presence of the ACTC transgene in Acta1 H40Y .ACTC mice.
DISCUSSION
In this study, we attempted to reduce the severity of disease in two mouse models of dominant skeletal muscle a-actin (ACTA1) disease by transgenically increasing the levels of cardiac a-actin in the skeletal muscle of these mice. The severity of the more severe dominant ACTA1 disease mouse model studied here, ACTA1 D286G .Acta1 +/2 mice, was significantly improved by delivering cardiac a-actin, but the severity of the second model, the Acta1 H40Y mice, was not. 
Acta1
+/2 .ACTC (n ¼ 6) and ACTA1 D286G.
Acta1 +/+ .ACTC (n ¼ 8) mice was collected over seven consecutive days. No significant difference in running activity between genotypes was calculated for (A) average distance per day, (B) average speed, and (C) maximum speed. .Acta1 +/2 mice, despite abundant nemaline bodies, ringbinden, internal nuclei and variation in myofibre size corresponds with the lack of correlation between muscle pathology and disease severity reported in patients (5), These data also suggest caution concerning the relevance of measuring the frequency of pathological features in animal models of ACTA1 and related diseases when evaluating the efficacy of treatments.
Western blotting confirmed increased relative levels of cardiac a-actin in the skeletal muscles of both ACTA1 D286G .Acta1 +/2 . ACTC and ACTA1
D286G
.Acta1 +/+ .ACTC mice (Fig. 3B and C) , which correlated with the desired outcome of decreasing the proportion of mutant D286G skeletal muscle a-actin protein (Fig. 3D) . Transgenic cardiac a-actin over-expression reduced the mutant D286G skeletal muscle a-actin load from 40% in severely affected ACTA1 D286G .Acta1
+/2 mice, to 20% in the ACTA1 D286G .Acta1 +/2 .ACTC mice with a significantly improved phenotype, a level akin to that detected in the only mildly affected ACTA1 D286G+/+ mice (31).
Acta1
H40Y .ACTC mice
In contrast to the findings achieved with the severe ACTA1 D286G .Acta1 +/2 mouse model, an amelioration of disease phenotype was not detected after introduction of the ACTC transgene to the Acta1 H40Y model. The survival rate of 20% of male Acta1 H40Y mice on the CBB6F1 background by 6 months of age was not improved (Fig. 5A) . The lower bodyweight of male and female Acta1 H40Y mice was also not counteracted by ACTC transgenic expression (Fig. 5B) .
Nemaline bodies and large 'actin lakes' were seen in 1-month-old EDL, gastrocnemius and quadriceps muscles from both male and female Acta1 H40Y .ACTC and Acta1 H40Y mice, but not in soleus muscles (Fig. 6A and B) . Similarly, electron microscopy demonstrated the presence of nemaline bodies and the thin filament accumulations in the predominantly fast twitch EDL and gastrocnemius muscles (Fig. 6C ). This finding of pathological lesions only within the predominantly fast twitch muscles, similar to expression of transgenes by skeletal muscle promoters (21, 32, 33) , was unexpected since endogenous skeletal muscle a-actin is expressed in both slow and fast twitch myofibres. Slow-twitch predominant myofibres may be selectively spared in mouse models of nemaline myopathy.
The few surviving 6-months-old male Acta1
H40Y
.ACTC mice showed striking skeletal muscle pathology, such as nemaline bodies and variation in myofibre size (Fig. 6D ) similar to surviving 6-months-old Acta1 H40Y male and female mice. Therefore the presence of the ACTC transgene did not appear to influence the severity of pathological features not unlike the ACTA1 D286G .Acta1 +/2 .ACTC mice described earlier.
Increased levels of cardiac a-actin in Acta1 H40Y mice
Unexpectedly, cardiac a-actin levels were increased in Acta1 H40Y mice, mice that do not have the ACTC transgene and to similarly high levels to Acta1 H40Y .ACTC mice with the ACTC transgene (Fig. 7A to D) . This suggests the ACTC transgene had little effect in increasing the levels of cardiac a-actin in this model beyond endogenous levels. As with the ACTC H40Y mice without the transgene was predominantly in MHCIIB myofibres (Fig. 7C) , with MHCIIA myofibres negative for cardiac a-actin (Fig. 7A -C) . In Acta1 H40Y muscle, only very occasional small myofibres showed double labelling for developmental MHC and cardiac a-actin, indicating that the majority of cardiac a-actin was being expressed in mature myofibres (Fig. 7A ) and was not due to the presence of regenerating, immature myofibres.
How the presence of the Acta1 H40Y knock-in allele evokes increased cardiac a-actin in MHCIIB myofibres is unclear. It could be hypothesized that the phenotype of the Acta1 H40Y mice would be more severe without the elevated levels of endogenously cardiac a-actin. Increased cardiac a-actin levels have not been reported for any patients with dominant ACTA1 disease (5), unlike patients with recessive ACTA1 disease who show upregulated cardiac a-actin levels (5,10). However, to our knowledge, muscle biopsies from patients with the p.H40Y ACTA1 mutation have not been tested for cardiac a-actin, so it is possible that increased cardiac a-actin levels may also occur in patients with the p.H40Y ACTA1 mutation.
The sex difference in severity in the Acta1 H40Y mice also remains unexplained. Sex difference in severity is not generally considered to occur in patients with dominant ACTA1 disease (2) . At the time Nguyen et al. published their study, two patients were known with p.H40Y ACTA1 mutations-a male who died at 2 months of age (6) and a female patient still alive at 51 years of age (18) . This at the time matched the phenotype in the Acta1 H40Y mice. However, one of two additional cases now in the ACTA1 locus-specific database (http://www.dmd.nl/nmdb2/home.php ?Select_db=ACTA1) is a severely affected female, which does not fit with the sex difference exhibited by the mouse model.
The fact that one p.H40Y ACTA1 patient is alive in her 50s indicates the H40Y mutation need not always be associated with a severe disease phenotype and suggests the existence of .ACTC mice is increased beyond wild-type mice, however, so is endogenous cardiac a-actin level in Acta1 H40Y mice. Cardiac a-actin (red), MHCIIA (blue) and developmental MHC (green) expression in gastrocnemius myofibres from 4-week-old Acta1 H40Y (A) and WT mice (B) demonstrates an elevated level of cardiac a-actin in Acta1 H40Y mice (aged 6-8 weeks old), without the ACTC transgene (aged 6-8 weeks old). Each image was taken of muscle from a different mouse and all images are taken under the same exposure settings to allow direct comparison of the fluorescence intensity for endogenous cardiac a-actin. All images are of muscle from male mice, except where indicated. Scale bars: 50 mm. (C) Immunostaining of Acta1 H40Y gastrocnemius muscle (8 weeks old) for cardiac a-actin (red), MHCIIA (blue) and MHC IIB (green). Scale bar: 50 mm. (D) Western blotting and (E) quantification of cardiac a-actin abundance in adult WT, TgACTC, Acta1 H40Y and Acta1
.ACTC muscle reveal high cardiac a-actin levels in Acta1 H40Y and Acta1
.ACTC mice. However, the ACTC transgene does not increase the amount of cardiac a-actin present in Acta1 H40Y mice.
Human
modifying factors. In the mice, obviously one factor is sex, but there must be other factors since some male mice also survive to adulthood. Indeed, family studies suggest there are modifiers of disease severity for other ACTA1 mutations (1). Our study demonstrates that cardiac a-actin over-expression in postnatal skeletal muscle can significantly lessen the disease severity of at least one dominant ACTA1 mutation: p.D286G. There is growing evidence that suggests the severity of the disease caused by most dominant ACTA1 mutations might be ameliorated by the upregulation of cardiac a-actin (6, 15, 17, 28) .
The effect of increasing levels of wild-type muscle actin on the phenotype of known dominant muscle actin mutations was recently investigated in the indirect flight muscles of Drosophila melanogaster (34) . The inability of the Drosophila expressing all seven mutant actins tested to fly was either completely or partially restored when an additional copy of the wild-type indirect flight muscle actin gene was introduced (34) .
In light of these results, the effect of over-expression of cardiac a-actin, should be examined on other dominant ACTA1 mutations. This would be more cost-effectively achieved in model systems more amenable to higher throughput screening, such as Drosophila melanogaster or Danio rerio. For example, it would be interesting to determine in the future whether a Drosophila model of the p.H40Y ACTA1 mutation could be rescued by either wild-type skeletal muscle or cardiac a-actin.
MATERIALS AND METHODS
Mouse lines
All animal procedures were approved by the Animal Experimentation Ethics Committee of The University of Western Australia. Table 1 shows the genotypes of all mice in the study, and the abbreviations used in this manuscript. TgACTA1 D286G+/+ .KOActa1
mice were previously created through breeding hemizygous skeletal muscle a-actin knock-out mice (KOActa1 +/2 ) (27) with TgACTA1 D286G+/+ mice (31) and were on a mixed CBB6F1ArcXFVB/n genetic background. The KIActa1
line (18) H40Y .ACTC, respectively).
Body mass and survival of lines
The body mass of ACTA1
D286G
.Acta1 +/2 , ACTA1
.Acta1 +/2 . ACTC and wild-type mice was determined at postnatal day 12, whereas for both male and female Acta1 H40Y , Acta1
H40Y
.ACTC and wild-type mice, the body mass was measured at 1 month of age.
Kaplan -Meier survival curves and log-rank tests were performed for the ACTA1 D286G .Acta1 +/2 strain versus the ACTA1 D286G .Acta1 +/2 .ACTC strain, and male mice for the KIActa1 H40Y+/2 versus the KIActa1 H40Y+/2 .ACTC strain.
Histology and immunohistochemistry
Freshly excised skeletal muscles were frozen in optimum cutting temperature medium using liquid nitrogen cooled isopentane. Gomori trichrome and hematoxylin and eosin staining were performed on 10 mm sections according to standard procedures (35) . Morphometry was investigated by determining mean fibre diameter on gastrocnemius myofibres at day 12-14 for ACTA1 D286G .Acta1 +/2 , ACTA1 D286G .Acta1 +/2 .ACTC and .ACTC 1-month-old mice (n ¼ 10) were measured for voluntary running wheel ability over seven consecutive days and compared with WT (n ¼ 25) and Acta1 H40Y (n ¼ 16) mice. No significant differences existed between Acta1
H40Y
.ACTC and Acta1 H40Y mice for all parameters (one-way ANNOVA). However, significant deficits are exhibited by the Acta1
.ACTC and Acta1
H40Y mice compared with WT mice for (A) average distance travelled per day, P , 0.0001 (both); (B) average speed, P , 0.0001 (both) and (C) maximum speed achieved, (P , 0.01, WT Vvs Acta1
; P , 0.005, WT vs Acta1 H40Y .ACTC).
* P , 0.01, * * P , 0.005, * * * P , 0.0001 relative to WT. H40Y (n ¼ 4) and wild-type (n ¼ 5) mice. Immunostaining was performed essentially as described previously (26) . Briefly, 10 mm frozen sections were blocked at room temperature for 1 h in 1% bovine serum albumin (BSA) and 10% fetal calf serum (FCS) in phosphate buffered saline (PBS). All mouse IgG 1 antibodies (developmental MHC, clone NCL-MHCd, diluted 1:10, Novocastra; clone MHCIIA, clone SC-71, diluted 1:3, DSHB; and cardiac a-actin, clone Ac1-20.4.2, diluted 1:20, Sigma) were conjugated to Zenon w AlexaFluors w (350, 488 or 594; Invitrogen), to facilitate visualization with minimal background. This cardiac a-actin antibody detects both endogenous and transgenic cardiac a-actin and does not cross-react with wildtype nor mutant skeletal muscle a-actins. Antibodies were incubated overnight at 48C diluted in the BSA/FCS solution. The MHCIIB antibody (mouse IgM; BF-F3, diluted 1:1, DSHB) without conjugation was also incubated overnight at 48C, and after three 5 min washes in PBS was then incubated for 1 h with a goat anti-mouse IgM AlexaFluor w 488 secondary antibody (incubated 1:1000). After final washes in PBS for all sections, they were mounted in Hydromount (National Diagnostics). Images were taken with an Olympus IX-71 fluorescent microscope using an Olympus DP-71 camera.
Following fixation with 2% paraformaldehyde, muscle sections were stained with a 1:1000 dilution of phalloidin-FITC to label filamentous (F-)actin, and the nuclei counterstained with Hoechst.
Electron microscopy (EM)
Excised skeletal muscles were cut into very thin strips before immersion in 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4. Osmium tetroxide (2%) was used to post-fix samples for 1 h, and they were then dehydrated through an ascending series of ethanols, embedded in araldite resin and cured for 24 h or more at 708C. An LKB 8800 ultramicrotome was utilized to cut ultrathin sections (70 nm), and a Philips CM-10 transmission EM to view grids. Grids were stained in saturated acidified uranyl acetate and lead citrate. Original negative film images captured were scanned to a digital format and saved as a jpeg file.
Liquid chromatography mass spectrometry-multiple reaction monitoring
The amount of D286G skeletal muscle a-actin protein was determined as described in Ravenscroft et al. (31) . The mass spectrometry technique in Nguyen et al. (18) was attempted for determining the amount of H40Y skeletal muscle a-actin protein, but in the current study was not efficacious at quantifying wild-type and H40Y skeletal muscle a-actin proteins.
Western blots and densitometry
Western blots were performed as per Nowak et al. (26) , with densitometry conducted using Image J.
Voluntary running wheel experiments
The voluntary activity of 1-month-old mice was monitored over 24 h periods for 7 consecutive days. Mice were housed singly in cages containing a standard mouse running wheel connected to a speedometer that recorded distance travelled, time spent moving, average and maximum speeds.
Statistics
GraphPad Prism 4 was used to conduct two-tailed Student's t-tests with Welch's correction for all the statistical analyses of two data sets and one-way ANOVAs for comparing more than two data sets. Where significance was obtained, NeumanKeuls multiple comparisons tests were employed. All data are presented as the mean + standard error of the mean, with n in parenthesis.
